
Treatment with Zinbryta caused reductions in the risk of 24-week confirmed multiple sclerosis disability progression.

Treatment with Zinbryta caused reductions in the risk of 24-week confirmed multiple sclerosis disability progression.

Targeted drug delivery focuses on diseased cells to minimize side effects on normal cells.

Study finds ultrasound should be included in the management of RA patients in clinical remission.

Significant decrease found in oral and intestinal microbial diversity during chemotherapy.

Alemtuzumab shows promise in multiple sclerosis patients who received prior disease-modifying therapy.

Arizona Cannabis Nurses Association seeks to expand medical marijuana access for chronic conditions, such as post-traumatic stress disorder.

Legislation will enable seniors in medically underserved communities to access pharmacist patient care services.

HHpgV-1 virus found in serum samples from blood transfusion recipients and hemophilia patients.

Opportunistic infections accounted for nearly one-fourth of all readmissions.

A pharmacy in Kentucky will pay $9.25 million to settle claims that it received money from Abbott for promoting a drug to nursing home patients.

Agreement will send nearly 500 million units of treatment over the course of 5 years to the World Federation of Hemophilia.

Just 5% of myeloma cases are in the first phase at diagnosis.

Families of children with cancer face food, housing, and energy insecurity.

Marc O'Connor, chief operating officer of Curant Health, discusses methods Curant uses to maintain adherence to specialty drug regimens.

Improvements in itching scores maintained from week 16 to week 52 in patients who received Otezla.

Inhibiting growth receptor presents promising treatment option.

HIV patients not on recommended regimens are less likely to achieve viral suppression and more likely to report side effects.

BRD4 gene could be exploited in treatment of acute myeloid leukemia.

MS prevalence increases in areas of higher latitude with decreased levels of sunlight exposure.

The National Institutes of Health (NIH) has awarded universities about $28 million in grants to study pediatric asthma triggers.

The FDA is considering expanding the use of Allergen's skin infection drug dalbavancin (Dalvance).

Did you know that the 14% of undiagnosed HIV patients cause 33% of new infections?

Exposure to benzene due to high traffic volume during childhood may contribute to disease development.

Top news of the week in cancer drug development.

Vitamin D deficiency may speed progression of the condition.

Ebola and AIDS spread rapidly in areas with poor health care systems.

Opdivo was previously approved for patients with squamous NSCLC whose disease progressed during or after platinum-based chemotherapy.

The FH Foundation helps guide patients on their journey to battle a silent killer.

Top stories of the week on Specialty Pharmacy Times.

Several genetic characteristics of more aggressive tumors significantly more prevalent in the African American community.